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Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid
TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high
prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed
from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We
analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically
well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB
chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after
two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and
extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB
chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care
test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10
DPS in TB high endemic countries.
T
uberculosis (TB) is amajor global health problem. An estimated 9million people develop TB disease and 1.5
million die of TB every year despite the fact that TB is a preventable disease1. The limitation of diagnostic
tools and insufficient follow-up of treatment pose amajor threat for the individual patient as well as to global
health. There is an urgent need of biomarkers to predict disease progression from latent tuberculosis (LTBI),
treatment efficacy and cure and as read-outs for immune responses to immunization2. Multi-drug resistant
(MDR)-TB poses a threat to global control of TB3,4 and has reinforced the need to find biomarkers that indicate
relapse-free treatment success5.
Interferon gamma inducible protein 10 (IP-10/CXCL-10), a pro-inflammatory chemokine involved in leu-
cocyte migration and activation, is a promising candidate as surrogate biomarker in TB infection6. IP-10 has been
investigated in a broad spectrum of infectious and non-infectious chronic inflammatory diseases7. The diagnostic
accuracy of IP-10 for TB infection seems to be on par with interferon gamma (IFN-c)-release assays (IGRAs), but
plasma IP-10 is expressed at a much higher level than IFN-c and thus considered a more robust marker8. Data
from both animal9,10 and human studies11–17 suggest that plasma IP-10 also has potential as a biomarker for
therapy responses in TB.
TheWorld Health Organization (WHO) and Stop TB Partnership have assigned 2015 for developing a simple
point-of-care (POC) test to ensure rapid TB diagnosis and treatment initiation. The potential impact, future
applications as well as challenges of POC tests have recently been reviewed by Dheda et al18. The filter paper
method, carried out either as dry blood spots (DBS) or dry plasma spots (DPS), has simplified diagnostics of
several diseases in resource-constrained settings19,20. However, to our knowledge, there are no previous studies of
IP-10 DPS during anti-TB chemotherapy. Thus, we aimed to compare the IP-10 DPS method with the direct
measurement of IP-10 in plasma analyzed by ELISA and investigate whether the IP-10DPSmethod could be used
to monitor treatment efficacy in TB infection.We report for the first time that plasma IP-10, as measured by both
methods, declined in response to anti-TB chemotherapy. Thus, our data indicate that the IP-10 DPS assay has
potential as a biomarker for treatment responses and TB cure and may be developed into use as a POC test in
resource-limited settings.
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Results
Study participants. Thirty-four TB patients were longitudinally
followed during 24 weeks of anti-TB chemotherapy. Thirty-two
patients were Mycobacterium tuberculosis (Mtb) culture-confirmed
whereas in two patients diagnosis was based on clinical suspicion,
findings on X-ray and a positive QuantiFERON-TB test. Demo-
graphic and clinical characteristics at inclusion are summarized in
Table 1. All patients were HIV-negative. There were 14 patients with
pulmonary TB (PTB) and 14 with extrapulmonary TB (EPTB), 3 with
combined PTB and EPTB, and 3 patients with disseminated TB. Sixteen
patients were classified into the ‘‘low symptom score’’ group and 18
patients into the ‘‘high symptom score’’ group. There was a tendency of
a higher symptom score in PTB compared to EPTB patients (p 5
0.057), in keeping with a higher proportion of PTB patients with an
erythrocyte sedimentation rate (ESR) .40 mm/hour (above the
median ESR for the cohort) (77% vs. 23%, p 5 0.017).
Thirty-one patients received standard first-line anti-TB chemo-
therapy (isoniazid, rifampicin, pyrazinamide and ethambutol)
whereas two patients received modified therapy with rifampicin,
pyrazinamide and ethambutol due to isoniazid resistance and one
patient received isoniazid, rifampicin and ethambutol due to pyra-
zinamide resistance. Five patients received extended standard anti-
TB chemotherapy for 9–12 months due to EPTB, disseminated TB
disease, drug resistance or lack of sputum conversion after 2 months
of therapy.
After 8 weeks of treatment, 13/14 (93%) of the PTB patients were
Mtb culture negative, whilst all PTB patients wereMtb culture nega-
tive after 12 weeks. All patients demonstrated clinical improvement
of TB disease during treatment, but four patients with glandular TB
experienced transient paradoxical increase of the lymph nodes. In
addition, two patients experienced worsening of gastrointestinal
symptoms during anti-TB chemotherapy; one with known Crohn’s
disease and one diagnosed with Crohn’s disease shortly after ini-
tiation of treatment. In both cases abdominal TB was excluded.
For the entire group of patients the ESR levels declined significantly
from baseline to the end of treatment [44 mm (5–111) to 8 mm (1–
52), p , 0.001].
Decline of plasma IP-10 during anti-TB chemotherapy. In the
plasma samples we observed an overall significant reduction in IP-
10 levels during 24 weeks of treatment (p 5 0.004). Plasma IP-10
declined significantly already from baseline to week 2 [221 pg/ml
(98–642) vs. 151 pg/ml (59–451), p 5 0.010] and to week 24
[99 pg/ml (56–269), p 5 0.011] (Fig. 1). Interestingly, IP-10 levels
in the two patients with Crohn’s disease as well as in one patient with
PTB responding to therapy with negative culture, but who had also
been treated for TB two years earlier, remained persistently elevated
during treatment (Fig. 2A). An apparent increase in IP-10 levels were
also seen in one of the EPTB patients who experienced paradoxical
lymphadenopathy during therapy, whereas patients with disse-
minated and resistant TB responded with decline in IP-10 levels
corresponding to clinical improvements.
Decline of IP-10 from Dried Plasma Spots (DPS) during anti-TB
chemotherapy. In the dried plasma spots, we also observed a
corresponding and overall significant reduction in IP-10 levels
during treatment (p , 0.001). DPS IP-10 levels declined
significantly already at week 2 [70 pg/2discs (17–120) vs. 20 pg/
2discs (3–67), p , 0.001], but in contrast to plasma IP-10, an
additional decline was observed at week 8 [8 pg/2discs (0–49), p 5
0.011] with stable levels towards week 24 [9 pg/2discs (0–30), p ,
0.001] (Fig. 1). A corresponding pattern as seen for individual
patients in the regular plasma IP-10 analyses was also found by the
DPS IP-10 method, but only the previously treated TB patient and
one of the patients with Crohn’s disease maintained IP-10 at high
levels (Fig. 2B).
Plasma IP-10 and DPS IP-10 correlate during anti-TB chemo-
therapy. IP-10 levels measured directly in plasma and after
extraction from DPS correlated well throughout treatment (r 5
0.75, p , 0.0001) (Fig. 3). The same positive correlation between
IP-10 levels measured by the twomethods was found in the PTB (r5
0.75, p , 0.001) and EPTB (r 5 0.77, p , 0.001) subgroups.
IP-10 levels according to symptom score and TB disease locali-
zation. Plasma IP-10 levels were analyzed in different clinical
subgroups of the study cohort. At baseline, the PTB group had
numerically, but not statistically, higher median IP-10 levels
compared to the EPTB group both in plasma samples [326 pg/ml
(94–1144) vs. 128 pg/ml (84–544), p 5 0.29] and in DPS samples
[80 pg/2discs (38–257) vs. 33 pg/2discs (7–83), p5 0.064] (Fig. 4A).
Further, we found at baseline significantly higher levels of IP-10 in
TB patients with ‘‘high symptom score’’ than in patients with ‘‘low
symptom score’’ both in plasma [483 pg/ml (115–1367) vs. 128 pg/
ml (67–326), p 5 0.005] and in DPS [88 pg/2discs (37–244) vs.
45 pg/2discs (2–82), p 5 0.010] (Fig. 4B). Finally, patients with
ESR . 40 had also significantly higher IP-10 levels than patients
with ESR , 40 both at baseline and after two 2 weeks (Fig. 4C).
Discussion
Biomarkers formonitoring of TB treatment are needed, especially for
use in patients with MDR-TB with long-lasting, insufficient and
demanding regimens. We report for the first time an early and par-
allel decline in plasma IP-10 levels after 2 weeks of efficient anti-TB
chemotherapy. The decline was accurately detectable in DPS with
good correlation between the two methods. Our data suggests that
the easy and manageable IP-10 DPS method could be used to mon-
itor treatment responses in patients with TB and possibly serve as a
POC test in resource-limited settings.
IP-10 has been studied in patients with various stages of TB infec-
tion in samples from peripheral blood21–26, pleural fluid27–29,
bronchoalveolar lavage30 and urine11. IP-10 may also improve TB
diagnosis both in HIV infection31–33 and in children34–36. However,
IP-10 is not specific for TB disease7, but seems to be upregulated in
many pro-inflammatory conditions including Hepatitis C infection
(HCV) where IP-10 has been used to predict the prospect of spon-
taneous clearance of acute HCV infection and treatment success in
chronically infected patients37,38.
Table 1 | Patient characteristics (N 5 34)
Age (median years, range) 30 (20–91)
Female (%) 15 (44)
Origin (%)
Africa 15 (44)
Asia 15 (44)
Europe 4 (12)
Localisation (%)
Pulmonary 14 (41)
Extrapulmonarya 14 (41)
Combined Pulmonary and Extrapulmonaryb 3 (9)
Disseminated TB 3 (9)
Drug sensitive Mtb5Mono-resistant Mtbc 3153
IGRA assayd (positive5negative5no data) 2150513
ESRe (median mm/hour, range) 39 (5–111)
Low5High symptom scoref 16518
aLymphnode, pericard, abdominal, cutaneous abscess, osteomyelitis.
bCulture growth from both pulmonary and extrapulmonary specimens.
cResistance for one of the standard first-line drugs.
dQuantiFERONH-TB.
eErythrocyte Sedimentation Rate.
fHigh 5 $2 of the following symptoms: fever (.38Cu), weight loss, wasting, cough and night-
sweat. Low 5 1 symptom or asymptomatic/detected by screening.
www.nature.com/scientificreports
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The decline in IP-10 levels as early as 2 weeks is in agreement
with experimental data from mouse models suggesting that IP-10 is
a responsive and dynamic biomarker9,10. In humans, Azzuri et al.12
found a significant decrease of plasma IP-10 in PTB patients after 2
months of treatment. A recent report by Hong et al. also found
significant reductions in unstimulated serum IP-10 after 6–9
months of treatment in a group with low-risk for relapse of TB
disease17. It has also been reported that IP-10 secretion after in vitro
stimulation with RD1 antigens decrease after 6 months of anti-TB
chemotherapy16.
The vast majority of patients with TB disease live in resource-
limited settings in low-income countries with restricted capacity to
diagnose TB disease and monitor treatment effect39. Sputum culture
conversion after 2 months of therapy may predict non-relapsing
cure, but has low sensitivity and modest specificity for predicting
failure and relapse of TB disease40. This emphasizes the need for
low-cost and easy-to perform diagnostic tools serving as POC tests
that can be handled in settings without electricity and cold chain
logistics. The filter paper method with DPS/DBS has previously been
used in resource-limited settings to diagnose and monitor both HIV
and CMV disease19,20. Aabye et al. have introduced a novel ELISA
based method for quantification of IP-10 extracted from DPS/DBS
and report a very good correlation to IP-10 levels measured directly
in plasma41. The use of IP-10 was also assessed in a TB validation
cohort, concluding that IP-10 was readily detectable in both plasma
and DPS with excellent correlation42. Finally, IP-10 is proven to be a
solid and robust marker in lateral flow assays delivering quantitative
results within short time in resource-poor settings43. Still, to our
knowledge, we are the first to explore the usefulness of DPS/DBS
as biomarker for therapy efficacy in TB. Our results revealed a good
correlation between IP-10 measured in plasma and DPS throughout
the treatment period. Thus, IP-10 measured by DPS has potential for
use as a field friendly tool allowing for real time monitoring of treat-
ment efficacy in resource-constrained settings such as DOTS clinics,
allowing for letter based sample transport for centralized analysis.
We have studied the performance of IP-10 in various clinical pre-
sentations of TB. EPTB is a diagnostic challenge; often pauci-bacil-
lary in nature and difficult to access for biopsies from TB affected
organs, especially during follow-up. We found higher IP-10 levels in
PTB patients than in the EPTB group due to presumed higher levels
of bacterial load in patients with PTB. However, this difference did
not reach statistical significance, which could be explained by the
heterogeneity of TB disease within the patient groups. Still, both
clinical groups responded to therapy with a decline in plasma IP-
10. Further, there were also significantly higher levels of IP-10 in the
patients with ‘‘high symptom score’’ and patients with high ESR in
accordance with studies showing elevated levels of IP-10 with
increasing severity of disease44,45.
Biomarkers must reliably predict TB cure and respond to react-
ivation or therapy failure. Although IP-10 levels declined in most
patients corresponding to bacterial clearance demonstrated by nega-
tive culture during follow-up, we observed fluctuating, incomplete or
unsuccessful reduction in IP-10 levels in some of the TB patients,
although not so apparent by the DPS method. This was seen in two
patients who experienced worsening due to inflammatory bowel
disease, but also in a patient facing a paradoxical reaction with an
intensification of glandular TB after initiation of anti-TB chemother-
apy. Increase in IP-10 levels have also been reported in patients who
relapsed after treatment12 and IP-10 identified patients with high risk
of cavitary TB disease as well as therapy failure with positive sputum
smear after 2months of treatment46. Altogether, these data show that
the pro-inflammatory chemokine IP-10 can respond with a dynamic
pattern to any sort of inflammation underscoring the importance to
clinically investigate further patients who experience a non-satisfact-
ory decline in IP-10 due to either treatment failure, TB relapse or
intercurrent co-morbidities.
Figure 1 | Dynamics of IP-10 in plasma and Dry Plasma Spots (DPS) during anti-TB chemotherapy. IP-10 levels measured in plasma and DPS in
patients with active TB during 24 weeks of effective anti-TB chemotherapy: Baseline (week 0) (N5 34), week 2 (N5 34), week 8 (N5 28), week 24 (N5
34). Box-whisker plots with median, interquartile ranges and min/max values indicated. P-values were calculated by Wilcoxon Signed Ranks test. A
significance level of 0.05 was used.
www.nature.com/scientificreports
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There are limitations in our study. The rather low numbers of
patients give reduced power in the statistical calculations and
increase the risk for Type 2 statistical errors. As our data indicate,
co-morbidities may also influence upon the elevated IP-10 levels
measured in this TB cohort. However, our patients were closely
monitored during treatment and worsening of symptoms and co-
morbidity was registered and correlated with the dynamics of IP-10
as described for individual patients. In addition, longer observations
andmeasurements of IP-10 after completion of TB therapy is needed
to evaluate the potential of IP-10 in predicting relapse of TB disease.
In conclusion our data suggest that an early decline of plasma IP-
10 levels may serve as a biomarker for anti-TB chemotherapy effi-
cacy. Further, as DPS IP-10 correlates well with plasma samples, this
manageable diagnostic tool has potential to assist in monitoring
treatment responses in resource poor settings. Thus, further pro-
spective studies must be performed to validate the use of IP-10
DPS or DBS detection by POC tests in TB high endemic areas.
Methods
Study participants. Thirty-four patients with TB were included in the study (Table 1).
Patients were categorized into pulmonary TB (PTB), extrapulmonary TB (EPTB),
combined PTB and EPTB, and in disseminated disease. The patients were grouped as
‘‘low symptom score’’ (asymptomatic or with one of the following symptoms; fever
.38Cu, weight loss, wasting, cough or night-sweat) or high symptom score (2 or more
symptoms). Blood samples were drawn into EDTA tubes at baseline and after 2, 8 and
24 weeks of standard anti-TB drug combination chemotherapy. Plasma was harvested
after centrifugation, snap-frozen and stored at – 80C until analysis.
Ethical considerations. The study was approved by the Regional Ethics Committee
and written informed consent was obtained from all participants. All experiments
were performed in accordance with relevant guidelines and regulations and the
plasma was stored in the departments approved biobank.
Filter Paper Sample Preparation. Preparation of the DPS was done according to
protocol as described by Drabe et al.47. Plasma samples were thawed and spotted in
Figure 2 | Comparison of Plasma andDry Plasma Spots (DPS) IP-10 in Individual patients during anti-TB chemotherapy. IP-10 levels during 24 weeks
of effective anti-TB chemotherapy in (A) plasma and (B)DPS in patients with active TB (N5 34): Baseline (week 0) (N5 34), week 2 (N5 34), week 8 (N
5 28), week 24 (N 5 34). 1Patient with pulmonary TB, previously treated (2 years earlier), but responding to present therapy with negative culture,
2Patient with Crohn’s disease diagnosed during TB treatment, 3Patient with paradoxical reaction of glandular TB during treatment, 4Patient with
disseminated TB and exacerbation of known Crohn’s disease from week 2.
Figure 3 | Correlation between IP-10 levels measured in plasma and Dry
Plasma Spots (DPS). Correlation between plasma samples and DPS for all
TB patients at all time-points during treatment (baseline, 2, 8 and 24
weeks). Correlation coefficients were calculated by Spearman’s rho
(significant values at the 0.01 level, 2-tailed).
www.nature.com/scientificreports
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23 25 ul volume on Whatman 903 filter paper (Whatman, USA) per sample and
allowed to air dry for 3–4 hours at ambient temperature. Filter paper samples were
stored in zip-lock plastic bags with a desiccant and sent by postal service from Oslo
University Hospital, Norway, to Statens Serum Instititute, Denmark.
Protocol for IP-10 Determination in plasma and DPS Samples.Detection of IP-10
in plasma and DPS samples was performed by ELISA according to protocols
developed by Aabye et al.41 and Drabe et al.47 respectively. In brief, plasma samples were
diluted five times in dilution buffer (2% BSA, 0.1% Tween-20 in PBS) with HRP-
conjungated detection mAb and allowed to incubate 2 hours in a mAb coated ELISA
plate. For DPS samples, two 6 mm filter paper discs were punched from the DPS (Harris
Puncher) and stacked horizontally in the bottom of a dry filter bottom plate (EMD
Millipore, USA). Following, 80 ul dilution buffer was added to each well of the filter
bottom plate and the DPS discs were allowed to rehydrate for 1 hour. Afterwards the filter
bottom plate was stacked on top of a coated IP-10 ELISA plate with 20 ul dilution buffer
with HRP-conjungated detection mAb and centrifuged at 4000 RPM for 5 minutes to
force the DPS disc elute into the ELISA plate. The ELISA plate was then incubated 1 hour
at room temperature. After incubation, plasma andDPS ELISA plates were washed3 3 in
PBS with 0.1% Tween-20 followed by addition of HRP substrate (TMB One, Trichem,
DK) and allowed to develop for 30 minutes before the color reaction was stopped and
absorbance was read at 450 nm subtracted air blank 630 nm. Plasma levels were corrected
for dilutions, DPS measurements are presented as pg/2 DPS discs.
Statistical analysis. Statistical analyzes were performed by SPSS statistics 22 (IBM).
Non-parametrical statistical methods were applied. Friedman test were used for
measuring overall differences at different time points during treatment. For group-
wise comparison Mann-Whitney U test was applied and for dependent variables the
two-tailed Wilcoxon matched pair test. Correlation analyses were performed using
Spearman’s rank correlation coefficient. 23 2 Fischer exact test was used in analysis
of categorical variables. A significance level of 0.05 was used. All values are presented
as median and interquartile range [IQR]. Graphical presentations were made using
Prism V5.04 and V6 software (GraphPad, San Diego, USA).
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